The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
Bottom Line: Optimal treatment and prevention of DN may require an early, intensive, multifactorial approach, tailored to simultaneously target all modifiable risk factors.Dipeptidyl peptidase (DPP)-4 inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels without additional risk of hypoglycaemia, and may also reduce albuminuria.Further investigation of the potential renal benefits of DPP-4 and SGLT2 inhibitors is underway.
Affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria email@example.com.Show MeSH
Related in: MedlinePlus
License 1 - License 2 - License 3
Mentions: Chronic kidney disease (CKD) is associated with various risk factors, including cardiovascular disease, obesity and diabetes. Between 1999 and 2004, the prevalence of CKD within the general US population was estimated to be 16.8% (Figure 1);5 the most recent prevalence estimate for 2007–2012 is 15.0%.6 CKD is more prevalent in those with diabetes and older patients (Figure 1).5 Worldwide, the reported prevalence rates vary widely from 2.5% in China to 35.8% in Finland (Table 1).33
Affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria firstname.lastname@example.org.